Launch of the UK Perioperative Medicine Clinical Trials Network
The National Institute for Academic Anaesthesia (NIAA) has announced the launch of the UK Perioperative Medicine Clinical Trials Network (CTN) at the inaugural NIAA Annual Scientific Meeting, held in London on Thursday 14th April 2016. New members are now able to join the CTN from this date.
The aim of the CTN is to build infrastructure to support patient recruitment into large clinical trials, and generate new evidence to inform the care of more than 300 million patients undergoing surgery worldwide each year. In keeping with the collaborative ethos of the NIAA, the CTN will create an environment which allows everyone with an interest in perioperative care to make a meaningful but realistic contribution to clinical trials and observational studies.
Professor Rupert Pearse, Director of the UK Perioperative Medicine Clinical Trials Network, said: "It's a great pleasure to launch the UK Perioperative Clinical Trials Network, which is a testament to the commitment of the National Institute for Academic Anaesthesia and our funding partners to delivering high quality research to improve the care of patients who need surgery. The Network represents a major step towards the delivery of large scale clinical trials and will place the UK as a world leader for research in this important but neglected area."
The CTN is overseen by the NIAA and funded by the Royal College of Anaesthetists (RCoA), the Association of Anaesthetists of Great Britain and Ireland (AAGBI), the Anaesthesia journal, the British Journal of Anaesthesia and the Rosetrees Trust.
The CTN has developed bespoke schemes suitable for investigators of all levels of experience. The Local Investigator scheme is accessible to all CTN members, while the Principal Investigator scheme is intended for members who will regularly take on local trial leadership responsibilities. The Chief Investigator scheme is for those members who are keen to progress from the Principal Investigator role on to one of a future leader of CTN-approved trials.
Share this :